CEO Today Business Women of the Year Awards
www.ceotodaymagazine.com 60 CEO Today Business Women of the Year Awards 2018 USA REBECCA TAUB Director, Founder, Chief Medical Officer and Executive Vice President of Madrigal Pharmaceuticals ABOUT REBECCA TAUB Rebecca Taub, M.D. has served as Chief Medical Officer and Executive Vice President, Research & Development, and as a member of our Board of Directors, since July 2016. Previously, Dr. Taub served as Chief Executive Officer and as a member of the Board of Directors of privately-held Madrigal Pharmaceuticals, Inc. from inception through its merger with Synta Pharmaceuticals Corp. Prior to joining Madrigal, Dr. Taub served as Senior Vice President, Research and Development of VIA Pharmaceuticals from 2008 to 2011 and as Vice President, Research, Metabolic Diseases at Hoffmann-La Roche from 2004 to 2008. In those positions, Dr. Taub oversaw clinical development and drug discovery programs in cardiovascular and metabolic diseases including the conduct of a series of Phase I and II proof of conduct clinical trials. Dr. Taub led drug discovery including target identification, lead optimization and advancement of preclinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and DuPont Pharmaceutical Company, in a variety of positions, including Executive Director of CNS and metabolic diseases research. Before becoming a pharmaceutical executive, Dr. Taub was a tenured Professor of Genetics and Medicine at the University of Pennsylvania. FIRM PROFILE Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company is developing MGL-3196, the first orally administered, small-molecule, liver- directed, truly β-selective thyroid hormone receptor (THR) agonist. In preclinical and Phase 1 studies, MGL-3196 has demonstrated a broad array of therapeutically beneficial effects, improving components of both metabolic syndrome, such as insulin resistance and dyslipidemia, and fatty liver disease, including lipotoxicity and inflammation.
Made with FlippingBook
RkJQdWJsaXNoZXIy Mjk3Mzkz